ExpreS2ion launches a new company website with increased focus on pipeline project development
Hørsholm, Denmark, September 29, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces the launch of a significantly upgraded company website. The new website has a stronger focus on ExpreS2ion’s novel technology platforms and the company’s pipeline project development. It also introduces a separate investor site for improved communication with shareholders, potential investors and other parties of interest.
Additional enhancements include easier access to ExpreS2ion’s online store, where customers are offered a broad range of viral antigens, transfection reagents and an ExpreS2 kit for starting up new development projects.
ExpreS2ion’s CEO Bent Frandsen comments:
“With promising vaccines for Covid-19 and breast cancer in development using our two novel technology platforms, while also providing development services and antigens to partners and customers, ExpreS2ion is now an established vaccine development company. I hope that our new website is able to convey this and strike a good balance between our business areas, so that we can continue to utilise it as an important tool in our communication with shareholders, partners and customers.”
The new website is available now at www.expres2ionbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telephone: +46 11 32 30 732
Email: ca@skmg.se
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.
Tags:
